Abstract:Abstract Variation is a hallmark of human tumors. Within any human tumor population, significant inter-tumor variation in genetic context underlies variation in phenotype, prognosis, and response to a given therapeutic agent. The ability to identify associations between genetic context and drug response lies at the core of much of translational research in cancer. However, current preclinical models fail to adequately represent this variation in a manner suitable for correlating genetic context with drug response. To address this challenge, we used complex genetically engineered murine tumors to develop a population based model comprising over 100 HER2 INK4A-/- driven breast tumors, each with associated expression microarray, array CGH, histology, as well as protein and biochemical characteristics. Similar to that observed in human tumor populations, this breast tumor archive exhibited significant inter-tumor variation in RNA and DNA profiles, and variation in many measurable tumor phenotypes, including tumor vasculature. The VEGF/VEGFR axis is postulated to be the dominant human tumor angiogenesis mediator. However, in contrast to robust activities observed in traditional xenograft models, anti-VEGF/VEGFR agents have thus far elicited relatively modest activity in human clinical studies (e.g. single agent RECIST response rates vary between 0–11% in several breast cancer studies). To better model the observed human variation in response to VEGF pathway antagonism, and to explore the development of a predictive biomarker for patient selection, we determined the responsiveness of tumors across the population based model to a potent, selective VEGFR inhibitor, tivozanib (AV-951). Tivozanib exhibits picomolar inhibitory activity against all three VEGF receptors, is active in a broad array of traditional xenografts, exhibits a multiday T1/2 in humans, and demonstrates robust clinical activity in renal cell carcinoma, with RECIST response rates of 25–40%. Interestingly, a significant variation in response to tivozanib was observed among 25 tumors in the population model, with the majority exhibiting intrinsic resistance to tivozanib's anti-angiogenic activity. Combining the efficacy data, extensive IHC analyses, the comprehensive expression profiles and a novel bioinformatics approach, we identified a multigene biomarker of on-target drug resistance. Using the same multigene biomarker identified in the murine model to examine human tumor microarray datasets, subsets of breast, lung, colon and kidney cancer human populations were predicted to exhibit tivozanib resistance. These data demonstrate the promise of population based preclinical models for translational research and provide a readily testable multigene biomarker for the potent VEGF pathway antagonist tivozanib. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B18.

Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor

Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models

First-in-human, Phase I Study of AK109, an Anti-Vegfr2 Antibody in Patients with Advanced or Metastatic Solid Tumors

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2)

Identification and Analysis of in Vivo Vegf Downstream Markers Link Vegf Pathway Activity with Efficacy of Anti-Vegf Therapies

Identification of a predictive biomarker and two pharmacodynamic biomarkers to ADG106 treatment, a novel anti-CD137 agonist antibody, in phase I clinical trials.

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

Amg 706, An Oral, Multikinase Inhibitor That Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, And Kit Receptors, Potently Inhibits Angiogenesis And Induces Regression In Tumor Xenografts

Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody.

Putting the brakes on angiogenesis through a novel VEGF–KLH (kinoid) vaccine

A Human IgG-like Bispecific Antibody Co-targeting Epidermal Growth Factor Receptor and the Vascular Endothelial Growth Factor Receptor 2 for Enhanced Antitumor Activity.

The Bispecific Antibody HB-32, Blockade of Both VEGF and DLL4 Shows Potent Anti-Angiogenic Activity in Vitro and Anti-Tumor Activity in Breast Cancer Xenograft Models.

Vegf Kinoid Vaccine, A Therapeutic Approach Against Tumor Angiogenesis And Metastases

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models

A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy

Optimized Expression And Characterization Of A Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 And Programmed Death-1 In Pichia Pastoris And Evaluation Of Antitumor Activity In Vivo

A Combination of 2D Similarity Search, Pharmacophore, and Molecular Docking Techniques for the Identification of Vascular Endothelial Growth Factor Receptor-2 Inhibitors

Abstract B18: Variation in Response to VEGFR Inhibitor Tivozanib in a Unique Population-Based Tumor Model Enables the Development of a Multigene Response Biomarker

Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer

Preclinical characterization of XB002, an anti-tissue factor antibody-drug conjugate for the treatment of solid tumors